Novel and emerging diabetes mellitus drug therapies for the type 2 diabetes patient

Table 3 Results of canagliflozin compared with sitagliptin for patients with type 2 diabetes: (n = 755)[16]

Parameters	Canagliflozin 300 mg	Sitagliptin 100 mg	Comments
A1c (%) week 52	-1.03	-0.66	Non inferiority to sitagliptin (upper limit of the 95%CI < 0.3%) and superiority to sitagliptin (upper limit of the 95%CI < 0.0%)
Percent (%) of patients with A1c < 7% at week 52	47.6	35.3	Not significant
Percent (%) of patients with A1c < 6.5% at week 52	22.5	18.9	Not significant
FPG (mg/dL) week 26	-29.9	-5.9	P < 0.001
Weight (kg)	-2.3	-0.1	P < 0.001
Change in systolic blood pressure (mmHg)	-5.1	0.9	P < 0.001
Change in diastolic blood pressure (mmHg)	-3.0	-0.3	Not significant

A1c: Hemoglobin A1c; FPG: Fasting plasma glucose.